Filing summary
Entity mismatch: The supplied filing is Semper Paratus Acquisition Corporation’s Form 10-K, not a Tevogen Inc. filing. The company identifies itself as a blank-check SPAC seeking a business combination, with a focus on transportation, supply chain and logistics.
Business context and reporting period
The annual report covers the fiscal year ended December 31, 2021. The financial statements report activity from incorporation on April 21, 2021 through year-end; they do not provide a standalone fourth-quarter results comparison. Semper Paratus completed its IPO on November 8, 2021 and had not begun operating a business or completed a business combination by year-end.
Financial results and liquidity
- Revenue: No operating revenue. Management said operating revenue was not expected before a business combination.
- Net loss: $28,745 for the period from inception through December 31, 2021. General and administrative expenses were $181,421; other income was $152,675, including $137,750 from a change in warrant fair value and $15,806 of trust-account investment income.
- Cash flow: The cash flow statement reports $713,826 used in operating activities, $351.9 million used in investing activities (primarily the trust deposit), and $352,958,406 provided by financing activities. The MD&A instead reports operating cash use of $713,825.
- Year-end liquidity: $344,581 in cash outside the trust account; $351,915,805 in trust-account cash and marketable securities. Working capital was $731,816. Trust funds were principally intended for a business combination or shareholder redemptions, not ordinary operating expenses.
- Debt and obligations: No long-term debt or borrowings under working-capital loans at year-end. The balance sheet includes $14.7 million of deferred underwriting fees payable only if a business combination is completed, plus $420,500 of derivative warrant liabilities.
- Capital structure: All 34.5 million IPO Class A shares were classified as redeemable temporary equity at $10.20 per share. The filing reports a $14.2 million shareholders’ deficit.
Changes versus prior period
This was the company’s first reporting period, and the filing provides no prior-year comparable results. The IPO raised $345 million in public-unit gross proceeds; a concurrent private placement raised $14.5 million. A total of $351.9 million was deposited in the trust account.
Outlook, risks and unusual items
- The company had until February 8, 2023, subject to any permitted extension, to complete a business combination; otherwise it generally had to redeem public shares and liquidate. Public warrants could expire worthless if no combination occurred.
- The auditor’s report includes a going-concern explanatory paragraph, citing a significant working-capital deficiency, losses and the need for additional funds. Management stated that these conditions raise substantial doubt about the company’s ability to continue as a going concern for one year from issuance of the financial statements. The statements contain no related adjustments.
- Management said additional financing might not be available on acceptable terms. It could reduce overhead, curtail operations or suspend its transaction search if it could not raise capital.
- COVID-19 and Russia’s invasion of Ukraine were cited as sources of uncertainty potentially affecting markets, the company’s financial condition and its search for a target; specific effects were not determinable.
- Potential conflicts include management and directors’ duties to other entities and possible related-party reimbursements, including a $10,000 monthly fee to a sponsor affiliate for office and support services. The filing also describes possible future sponsor or affiliate loans, including up to $1.5 million convertible into units at the lender’s option.
- The sponsor’s trust-account indemnity has exclusions, and the filing says the sponsor’s ability to satisfy it was not assured. Third-party or creditor claims could reduce funds available to public shareholders.
Investor verification priorities
- Confirm the issuer and filing: this document is for Semper Paratus Acquisition Corporation, not Tevogen Inc.
- Review the audited statements and notes for the going-concern language, unrestricted operating cash, redeemable shares and deferred underwriting fees.
- Reconcile the $1 difference in reported operating cash used between the MD&A and cash flow statement.
- Verify any subsequent business-combination, extension, redemption or liquidation developments after the December 31, 2021 reporting date.
- Assess sponsor-indemnity limitations, creditor-claim exposure, related-party payments and potential dilution from founder shares, warrants or future financing.